Temozolomide Rechallenge in Recurrent Glioblastoma: When is it Useful?
- 9 May 2018
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 14 (11) , 1063-1069
Abstract
Aim: To identify patients with recurrent glioblastoma after temozolomide (TMZ) concurrent with and adjuvant to radiotherapy who could benefit from TMZ rechallenge at the time of disease progression. Methods: We retrospectively evaluated 106 glioblastoma patients who had nonprogressive disease at first magnetic resonance imaging after completion of TMZ concurrent with and adjuvant to radiotherapy, a treatment-free interval (TFI) of at least 8 weeks and received TMZ rechallenge or a nitrosourea at the time of progression. Results: In patients with TFI ≥5 months, median survival was 17.7 and 11.6 months and median progression-free survival was 8.1 and 5.8 months in the TMZ and nitrosourea group, respectively. Longer TFI was associated with reduced risk for death (p = 0.002) and for disease progression (p = 0.005). Conclusion: TFI ≥5 months represents a predictor of retained TMZ sensitivity.Keywords
This publication has 24 references indexed in Scilit:
- Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant gliomaNeuro-Oncology, 2012
- Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective studyJournal of Neuro-Oncology, 2012
- Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE StudyJournal of Clinical Oncology, 2010
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)Cancer Chemotherapy and Pharmacology, 2009
- Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide scheduleCancer, 2008
- Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)British Journal of Cancer, 2006
- Salvage temozolomide for prior temozolomide respondersCancer, 2005
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005